These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

615 related items for PubMed ID: 11041566

  • 1. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
    Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S, Cohen A, Körbling MJ, Manning J, Romaguera J, Sarris A, Rodriguez, Hagemeister F, Mclaughlin P, Cabanillas F, Champlin RE.
    Bone Marrow Transplant; 2000 Sep; 26(6):615-20. PubMed ID: 11041566
    [Abstract] [Full Text] [Related]

  • 2. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R.
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [Abstract] [Full Text] [Related]

  • 3. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
    Devine SM, Sanborn R, Jessop E, Stock W, Huml M, Peace D, Wickrema A, Yassine M, Amin K, Thomason D, Chen YH, Devine H, Maningo M, van Besien K.
    Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
    [Abstract] [Full Text] [Related]

  • 4. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen.
    Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE.
    Bone Marrow Transplant; 2005 May; 35(10):943-51. PubMed ID: 15806128
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation.
    Wäsch R, Reisser S, Hahn J, Bertz H, Engelhardt M, Kunzmann R, Veelken H, Holler E, Finke J.
    Bone Marrow Transplant; 2000 Aug; 26(3):243-50. PubMed ID: 10967561
    [Abstract] [Full Text] [Related]

  • 9. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group.
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease.
    Claviez A, Klingebiel T, Beyer J, Nürnberger W, Ehninger G, Suttorp M, Dreger P, Dörffel W, Schmitz N.
    Ann Hematol; 2004 Apr; 83(4):237-41. PubMed ID: 14625790
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP, Chen CS, Tai BC, Hwang WY, Tan LK, Ng HY, Linn YC, Koh MB, Goh YT, Tan B, Lim S, Lee YM, Tan KW, Liu TC, Ng HJ, Loh YS, Mow BM, Tan DC, Tan PH.
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [Abstract] [Full Text] [Related]

  • 15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 16. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
    Pedrazzoli P, Da Prada GA, Giorgiani G, Schiavo R, Zambelli A, Giraldi E, Landonio G, Locatelli F, Siena S, Della Cuna GR.
    Cancer; 2002 May 01; 94(9):2409-15. PubMed ID: 12015766
    [Abstract] [Full Text] [Related]

  • 17. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
    Schetelig J, Bornhäuser M, Kiehl M, Schwerdtfeger R, Kröger N, Runde V, Zabelina T, Held TK, Thiede C, Fauser AA, Beelen D, Zander A, Ehninger G, Siegert W, Cooperative German Transplant Study Group.
    Bone Marrow Transplant; 2004 Mar 01; 33(5):483-90. PubMed ID: 14716342
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR, McAfee S, Sackstein R, Colby C, Saidman S, Weymouth D, Poliquin C, Vanderklish J, Sachs DH, Sykes M, Spitzer TR.
    Biol Blood Marrow Transplant; 2001 Mar 01; 7(11):604-12. PubMed ID: 11760148
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.